{"id":"eplivanserin-sr46349","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Insomnia"}]},"_chembl":{"chemblId":"CHEMBL257704","moleculeType":"Small molecule","molecularWeight":"328.39"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug selectively blocks 5-HT2A receptors, which are involved in inhibiting sexual function. By antagonizing these receptors, eplivanserin enhances sexual arousal and function. This mechanism targets the central nervous system's serotonergic pathways that suppress sexual response.","oneSentence":"Eplivanserin is a selective serotonin 5-HT2A receptor antagonist that modulates serotonergic signaling to treat sexual dysfunction.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:11:13.712Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypoactive sexual desire disorder (HSDD) in premenopausal women"}]},"trialDetails":[{"nctId":"NCT00805350","phase":"PHASE3","title":"Efficacy and Safety of Eplivanserin 5mg/Day in Insomnia Characterized by Sleep Maintenance Difficulties","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-12","conditions":"Primary Insomnia","enrollment":637},{"nctId":"NCT00253968","phase":"PHASE3","title":"Efficacy and Safety of Eplivanserin Treatment for Sleep Maintenance Insomnia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-11","conditions":"Sleep Initiation and Maintenance Disorders, Insomnia","enrollment":967},{"nctId":"NCT00308503","phase":"PHASE3","title":"Efficacy and Safety of Eplivanserin 5mg/Day on Sleep Maintenance Insomnia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-02","conditions":"Sleep Initiation and Maintenance Disorders, Insomnia","enrollment":608},{"nctId":"NCT00253903","phase":"PHASE3","title":"Efficacy and Safety of Eplivanserin Treatment for Sleep Maintenance Insomnia Followed by Optional Extension up to 1 Year","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-11","conditions":"Sleep Initiation and Maintenance Disorders, Insomnia","enrollment":1155},{"nctId":"NCT00679900","phase":"PHASE3","title":"Comparison of Eplivanserin and Lormetazepam in the Treatment of Insomnia Characterized by Sleep Maintenance Difficulties","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-04","conditions":"Sleep Initiation and Maintenance Disorders","enrollment":283},{"nctId":"NCT00313885","phase":"PHASE2","title":"Efficacy and Safety of SR46349B in Patients With Sleep Disorders in Fibromyalgia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-04","conditions":"Fibromyalgia, Sleep, Chronic Pain","enrollment":205},{"nctId":"NCT00913614","phase":"PHASE1","title":"Single Dose Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Evaluation of Eplivanserin in Children With Insomnia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-06","conditions":"Sleep Initiation and Maintenance Disorders","enrollment":41}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Eplivanserin (SR46349)","genericName":"Eplivanserin (SR46349)","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Eplivanserin is a selective serotonin 5-HT2A receptor antagonist that modulates serotonergic signaling to treat sexual dysfunction. Used for Hypoactive sexual desire disorder (HSDD) in premenopausal women.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}